|
(Health-NewsWire.Net, December 07, 2021 ) The Research Report on "Metabolomics Market by Product (GC,UPLC, CE, Surface based Mass Analysis), Application (Biomarker Discovery, Drug Discovery,Functional Genomics), Indication (Cardiology, Oncology,Inborn Errors), End User (Academic Institute,CROs) - Global Forecast to 2025" The global metabolomics technology market size is projected to reach USD 4.1 billion by 2025, at a CAGR of 13.4% between 2020 and 2025.
Growth Opportunity: Biomarker development;
Metabolomics is used to identify new biomarkers through bioinformatics tools, which indicate the changes in the physiological state of a cell or tissue. Biomarkers are important for developing in-vitro diagnostic tools, environmental toxicology screening methods, and drug discovery and development techniques. The omics revolution of the last decade has increased the application of metabolomics in biomedical research. As a result of these technological developments, new biomarkers are being regularly discovered. These biomarkers are required in medical sciences to better define and diagnose diseases, predict adverse drug events, and identify patient groups who would benefit from specific treatments. Moreover, in the near future, identifying biomarkers related to safety, sensitivity, and resistance to commercially available drugs will present significant growth opportunities for the metabolomics technology market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=900
Industry Segmentation In Detailed:
Separation tools accounted for the largest share in the metabolomics market in 2019.
Based on the product & service, categorized into metabolomics instruments and bioinformatics tools and services. The metabolomics instruments segment is further categorized into separation tools and detection tools. Separation tools is sub segmented into gas chromatography, high-performance liquid chromatography, ultra-performance liquid chromatography, and capillary electrophoresis. Similarly, detection tools are categorized into nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and surface-based mass analysis. The separation tools segment accounted for the largest share of the metabolomics market in 2019. The widespread use of separation tools in research activities, increase in funds for research projects, development of innovative technologies in these tools, and their extensive application in the drug discovery process are fueling the growth of this segment.
Cancer accounted for the largest share in the metabolomics market in 2019
Based on indication, segmented into into cancer, cardiovascular disorders, neurological disorders, metabolic disorders, inborn errors of metabolism, and other indications. The cancer segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the growing use of metabolomics in cancer research and increasing number of cancer patients.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=900
Leading Key Players and Analysis:
The metabolomics market is dominated by a few globally established players such as Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific (US), Danaher Corporation (US), Bruker Corporation (US), PerkinElmer (US), Merck KGaA (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan), Human Metabolome Technologies, Inc. (Japan), LECO Corporation (US), Metabolon, Inc. (US), Bio-Rad Laboratories (US), Scion Instruments (US), DANI Instruments S.p.A. (Italy), GL Sciences (Japan), SRI Instruments (US), Kore Technology Ltd. (UK), and JASCO, Inc. (US) among others.
Agilent Technologies (U.S.) is another leading company in the global metabolomics market. The company has maintained its leadership position through its strong presence across the globe, covering major markets such as North America, Europe, and Asia-Pacific. The company has a strong product portfolio and its FDA and CE Mark-approved products have helped it to further enhance its presence in the metabolomics market. The company has adopted new product launches as its key strategy, followed by agreements and collaborations, to maintain its leading position and increase its market share. For instance, in December 2016, Agilent Technologies, Inc. (U.S.) collaborated with Transcriptic Inc. (U.S.), a robotic cloud-based biotechnology laboratory, to develop and provide rapid and efficient technologies for broad scale synthetic and discovery.
Geographical Analysis in Detailed:
The global metabolomics market is segmented into North America, Europe, the Asia Pacific, Latin Ametica and Middle East & Africa. In 2019, North America accounted for the largest share of the metabolomics technology market. The large share of the North America region can be attributed to the presence of major players operating in the market in US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=900
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
